The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Ruxolitinib discontinuation syndrome: real-world data
Francesca Palandri
• 16 Jun 2020
Francesca Palandri, PhD, MD, of the University Hospital, Bologna, Italy, discusses real-world data on the incidence of ruxolitinib discontinuation syndrome in myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
